Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Universal Allogeneic CD19/BCMA CAR-T in Autoimmune Diseases
NCT07155369Phase 1Active, not recruiting
- Sponsor
- The Affiliated Hospital of Xuzhou Medical University
- Start
- Mar 2025
- Primary completion
- Sep 2026
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of anti-CD19/BCMA CAR T-cells in systemic lupus erythematosus (SLE) and systemic sclerosis (SSc), sponsored by The Affiliated Hospital of Xuzhou Medical University. Primary endpoints: Safety and tolerability of UCAR T-cell at 2 years and Clinical responses and duration of UCAR-T cells at 2 years. Started Mar 2025; status: active, not recruiting.
02
Drugs
anti-CD19/BCMA CAR T-cells
03
Conditions
systemic lupus erythematosus (SLE)systemic sclerosis (SSc)
Beyond the preview
Go deeper on NCT07155369.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07155369.